ACTRN12613000172707已完成未知
For persons with diabetes, will a web- and mobile phone-based intervention (myCompass) reduce symptoms of depression
A/Professor Judy Proudfoot0 个研究点目标入组 200 人开始时间: 2013年2月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 75 Years（—）
- 性别
- All
入选标准
- •To be eligible, participants must:
- •- have type 1 or type 2 diabetes, diagnosed by a GP or endocrinologist
- •- have no previous experience with the myCompass program
- •- be 18 - 75 years of age
- •- be literate in English
- •- have access to a computer, the internet and a valid email address
- •- have access to an internet enabled mobile phone
- •- be experiencing at least mild depression
排除标准
- •Psychosis (as measured by the Psychosis Screening Questionnaire, Bebbington, 1995)
研究者
相似试验
尚未招募
Unknown
TO EVALUATE THE STATUS OF DIABETES MELLITUS AMONG FIRST TRIMESTER PREGNANT WOMECTRI/2023/05/053343Dr AKSHATA CHIKALI
进行中（未招募）
1 期
Double-blind, randomised, placebo-controlled trial of nicotine replacement therapy in pregnancy - Smoking, Nicotine and Pregnancy (SNAP) TrialSmoking during pregnancy Specifically smoking 5 or more cigarettes currently (i.e. whilst pregnant) and having smoked 10 or more cigarettes prior to pregnancy.EUCTR2004-002621-46-GBniversity of Nottingham1,050
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFthe prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (AF)MedDRA version: 9.1Level: LLTClassification code 10003658Term: Atrial fibrillationEUCTR2008-003698-42-DKAstraZeneca AB14,600
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFEUCTR2008-003698-42-SEAstraZeneca AB14,600
进行中（未招募）
不适用
A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF) - ASSURE-AFEUCTR2008-003698-42-BGAstraZeneca AB14,600